Factor V Leiden mutation (R506Q) and the risk of advanced retinopathy of prematurity.
The coagulation factor V Leiden mutation was reported to be a significant (10.7%) risk factor for pre-term deliveries. It is also well known that a portion (10%) of very low birth weight premature babies develop advanced retinopathy of prematurity (ROP) which is a leading cause of blindness in children. However, the relationship between the Leiden mutation and development of advanced ROP is not known. In order to understand this relationship as well as genetic contribution to ROP, in this study, we have analyzed 100 pre-term infants with advanced ROP (stage 4B/5), 20 term babies with a clinically similar disease called familial exudative vitreoretinopathy (FEVR) and 16 normal babies from four different ethnic backgrounds. Our extensive analysis has identified a heterozygous Leiden mutation in four patients (4%) with advanced ROP and in one patient (5%) with sporadic FEVR. DNA sequence analysis has further confirmed this base change as well as heterozygosity. However, the frequency observed in the patients analyzed in our study is lower than reported frequency in the general population (5.4%). Therefore, statistically factor V mutation on its own is not a major risk factor for the above two disorders. However, it may be associated with other additive factors as might be expected for a complex genetic trait.
Kleinberg
Sarah
S
Department of Biological Sciences, Oakland University, Rochester, MI 48309-4401, USA.
Garrant
Scott
S
Tillen
Terri
T
Trese
M T
MT
Shastry
B S
BS
D001483:Base Sequence; D004262:DNA Restriction Enzymes / Q000494:pharmacology; D005165:Factor V / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008969:Molecular Sequence Data; D009154:Mutation; D012178:Retinopathy of Prematurity / Q000235:genetics*; D018630:Vitreoretinopathy, Proliferative / Q000235:genetics
D005165:Factor V; D004262:DNA Restriction Enzymes